Burger's Medicinal Chemistry and Drug Discovery: Provisional BCS Classification of the Leading Oral Drugs on the Global Market

Arik Dahan, Gordon Amidon

    Research output: Chapter in Book/Report/Conference proceedingChapter

    Abstract

    In the early 1990s, a collaborative research effort between academia and the U.S. Food and Drug Administration (FDA) was initiated to establish a database of human jejunal permeabilities based on a Biopharmaceutics Classification System (BCS). The BCS broadly allowed the prediction of human absorption, Fraction absorbed (Fabs) and the rate-limiting step in the intestinal absorption process of drugs following oral administration. The BCS classified compounds into one of four biopharmaceutical classes according to water solubility and membrane permeability characteristics. Today, the BCS has generated remarkable impact on the global pharmaceutical sciences arena, in drug discovery, development and regulation, and an extensive validation/discussion of the BCS is continuously published in the literature. BCS has been effectively implanted by drug regulatory agencies around the world, and widely practiced by the pharmaceutical industry. The aim of this chapter is to present the BCS and its scientific basis, to describe its impact on regulatory practice of oral drug products, and to access the BCS classification of the top drugs on the global market. Finally, current and future directions in BCS related extensions, and their impact on the pharmaceutical industry, will be discussed.Keywords:BCS;BA/BE;biowaiver;oral drug product;intestinal absorption
    Original languageEnglish
    Title of host publication Burger's Medicinal Chemistry and Drug Discovery
    DOIs
    StatePublished - 15 Apr 2010

    Fingerprint

    Dive into the research topics of 'Burger's Medicinal Chemistry and Drug Discovery: Provisional BCS Classification of the Leading Oral Drugs on the Global Market'. Together they form a unique fingerprint.

    Cite this